Search

Contributor:

Diana Do, MD, and Ramin Tadayoni, MD, PhD

Angiogenesis 2021: Wet AMD

Clinical Impacts From AAO 2020: Drs. Singh, Do, and Heier

Angiogenesis 2021: Wet AMD

High-Dose Aflibercept in the Real World

High-Dose Aflibercept in the Real World

Diana Do, MD

Response to Protocol V: Is Observation a Wise Approach to DME with 20/25 Vision?

Response to Protocol V: Is Observation a Wise Approach to DME with 20/25 Vision?

Diana Do, MD, and Ramin Tadayoni, MD, PhD

Extension Data for High-Dose Aflibercept

Extension Data for High-Dose Aflibercept

Diana Do, MD

Flexible Dosing for High-Dose Aflibercept: The Data

Flexible Dosing for High-Dose Aflibercept: The Data

Diana Do, MD

High-Dose Aflibercept: 48-Week Data

High-Dose Aflibercept: 48-Week Data

Diana V. Do, MD, FASRS

Promising Anatomic Outcomes from LIGHTSITE III Trial

Promising Anatomic Outcomes from LIGHTSITE III Trial

Diana V. Do, MD, and Glenn J. Jaffe, MD

Valeda Demonstrates Vision Improvement in Patients with Dry AMD

Valeda Demonstrates Vision Improvement in Patients with Dry AMD

Diana V. Do, MD, and Glenn J. Jaffe, MD

Comparing the Efficacy of Intravitreal Anti-VEGF Agents in the Treatment of Wet AMD

Comparing the Efficacy of Intravitreal Anti-VEGF Agents in the Treatment of Wet AMD

Diana V. Do, MD

Exploring DME Outcomes Based on Baseline Vision

Exploring DME Outcomes Based on Baseline Vision

Diana V. Do, MD

Angiogenesis 2021: Wet AMD

John Kitchens, MD; Diana Do, MD; and Carl Regillo, MD

ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation Data

Marion Munk, MD, PhD; and Diana Do, MD

Clinical Impacts From AAO 2020: Drs. Singh, Do, and Heier

Rishi Singh, MD; Diana Do, MD; and Jeffrey Heier, MD

New Retina Radio ARVO Coverage: DME Update: 8-mg Aflibercept data and Faricimab TAE in Phase 3

Diana Do, MD; and Jennifer Lim, MD

New Treatment Options and Considerations for AMD

Allen C. Ho, MD; Robyn Guymer AM, MBBS, PhD, FRANZCO, FAHMS; Charles C. Wykoff, MD, PhD; and Diana V. Do, MD